[(Z)-Prop-2-ynyloxyimino]-[2-(trityl-amino)-thiazol-4-yl]-acetyl chloride | 112258-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: [(Z)-Prop-2-ynyloxyimino]-[2-(trityl-amino)-thiazol-4-yl]-acetyl chloride
• CAS: 112258-88-5
• 化学式: C₂₇H₂₀ClN₃O₂S
• 分子量: 485.994
• InChiKey: CFBYDVRLJURTRF-QLTSDVKISA-N

物化性质

• 沸点：
  639.8±65.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

反应信息

• 作为反应物：
  描述：

  [(Z)-Prop-2-ynyloxyimino]-[2-(trityl-amino)-thiazol-4-yl]-acetyl chloride 在 N-甲基吗啉 、 三乙基硅烷 、 palladium diacetate 、 三苯基膦 、 三氟乙酸 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 3.17h， 生成 LY207197
  参考文献：
  名称：

  Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters

  摘要：

  The structure-activity relationship among a series of novel pyrazolidinone antibacterial agents is described. Specifically, the effect of modification of the side chain attached to the nitrogen at C-7 was explored in an attempt to improve the potency and spectrum of activity. This approach was successful in identifying several compounds having good in vitro profiles. These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored. This information proved critical for the identification of candidates for clinical evaluation.

  DOI：

  10.1021/jm00074a002
• 作为产物：
  描述：

  (2Z)-2-prop-2-ynoxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetic acid 在 N-甲基吗啉 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 生成 [(Z)-Prop-2-ynyloxyimino]-[2-(trityl-amino)-thiazol-4-yl]-acetyl chloride
  参考文献：
  名称：

  Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters

  摘要：

  The structure-activity relationship among a series of novel pyrazolidinone antibacterial agents is described. Specifically, the effect of modification of the side chain attached to the nitrogen at C-7 was explored in an attempt to improve the potency and spectrum of activity. This approach was successful in identifying several compounds having good in vitro profiles. These top candidates were then evaluated for their activity in vivo, and their pharmacokinetic behavior in various animal models was explored. This information proved critical for the identification of candidates for clinical evaluation.

  DOI：

  10.1021/jm00074a002